Gammagard
Gammagard is a brand-name immune globulin product (also known as IVIG) used to treat patients with immune deficiencies and certain autoimmune conditions. It provides passive immunity by supplying antibodies derived from human plasma. This medication is administered intravenously and requires supervision by healthcare professionals.
Gammagard is an intravenous immune globulin therapy used to treat primary immunodeficiencies and certain autoimmune disorders by providing replacement antibodies.
Key facts at a glance
- RxNorm
- 42697
- Generic
- Gammagard
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Gammagard is used to treat primary humoral immunodeficiency (including X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiency). It is also used for immune thrombocytopenic purpura (ITP), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy. Additionally, it may be used in certain patients undergoing bone marrow transplantation.
Gammagard contains pooled antibodies (immunoglobulin G) from human plasma donors. It provides passive immunity by replacing deficient or missing antibodies, allowing the body to fight infections. The exact mechanism in autoimmune conditions is not fully understood but is believed to involve immunomodulatory effects on the immune system.
Gammagard is administered via intravenous infusion by healthcare professionals. Common side effects include headache, chills, fever, and infusion reactions. It carries a risk of blood clots, kidney problems, and theoretically could transmit infectious agents despite screening. Patients should be well-hydrated before infusion and monitored during administration. Product availability and formulation details should be confirmed with current manufacturer information.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy